PTC Therapeutics, Inc.

NasdaqGS:PTCT Stok Raporu

Piyasa değeri: US$3.3b

PTC Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

PTC Therapeutics CEO'su Matt Klein, Mar2023 tarihinde atandı, in görev süresi 1.67 yıldır. in toplam yıllık tazminatı $ 8.94M olup, şirket hissesi ve opsiyonları dahil olmak üzere 8.4% maaş ve 91.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.068% ine doğrudan sahiptir ve bu hisseler $ 2.27M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.7 yıl ve 9.4 yıldır.

Anahtar bilgiler

Matt Klein

İcra Kurulu Başkanı

US$8.9m

Toplam tazminat

CEO maaş yüzdesi8.4%
CEO görev süresi1.7yrs
CEO sahipliği0.07%
Yönetim ortalama görev süresi5.7yrs
Yönetim Kurulu ortalama görev süresi9.4yrs

Son yönetim güncellemeleri

Recent updates

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth

Oct 09
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth

PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value

Sep 12

Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues

Jun 28
Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues

PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna

May 22

Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%

May 22
Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%

PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts

May 14

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Mar 03
PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

Feb 11

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Jun 23
An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

May 18
Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Mar 02
An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.

Oct 19

PTC Therapeutics betas topline expectations, strengthens commercial portfolio

Aug 05

PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder

Jul 20

PTC Therapeutics: DMD Trial News Unlikely To Restore Flagging Share Price

Jun 24

CEO Tazminat Analizi

Matt Klein'un ücretlendirmesi PTC Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$453m

Jun 30 2024n/an/a

-US$480m

Mar 31 2024n/an/a

-US$579m

Dec 31 2023US$9mUS$747k

-US$627m

Sep 30 2023n/an/a

-US$642m

Jun 30 2023n/an/a

-US$618m

Mar 31 2023n/an/a

-US$571m

Dec 31 2022US$5mUS$598k

-US$559m

Tazminat ve Piyasa: Matt 'nin toplam tazminatı ($USD 8.94M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 6.56M ).

Tazminat ve Kazançlar: Matt şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Matt Klein (52 yo)

1.7yrs

Görev süresi

US$8,937,025

Tazminat

Dr. Matthew B. Klein, also known as Matt, M.D., MS, FACS, serves as Chief Executive Officer and Director of PTC Therapeutics, Inc. since March 24, 2023He served as an Independent Director at ClearPoint Neu...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Matthew Klein
CEO & Director1.7yrsUS$8.94m0.068%
$ 2.3m
Stuart Peltz
Co-Founder26.8yrsUS$5.66mVeri yok
Allan Jacobson
Co-Founder26.8yrsUS$511.98k0.016%
$ 533.8k
Pierre Gravier
Chief Financial Officer1.3yrsUS$3.01m0.015%
$ 515.8k
Mark Boulding
Executive VP & Chief Legal Officer12.7yrsUS$2.19m0.063%
$ 2.1m
Eric Pauwels
Chief Business Officer9.6yrsUS$2.41m0.026%
$ 852.9k
Lee Golden
Executive VP & Chief Medical Officer4.5yrsUS$2.39m0.019%
$ 642.8k
Christine Utter
Senior VP5.4yrsUS$1.70m0.022%
$ 737.2k
Neil Almstead
Chief Technical Operations Officer5.9yrsUS$2.67m0.054%
$ 1.8m
Linda Carter
Senior VP & Chief Information Officerless than a yearVeri yokVeri yok
Alex Kane
Investor Relations Officerno dataVeri yokVeri yok
Jane Baj
Vice President of Corporate Communicationsno dataVeri yokVeri yok

5.7yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: PTCT 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.7 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Matthew Klein
CEO & Director1.7yrsUS$8.94m0.068%
$ 2.3m
Stuart Peltz
Co-Founder1.7yrsUS$5.66mVeri yok
Allan Jacobson
Co-Founder26.8yrsUS$511.98k0.016%
$ 533.8k
Michael Schmertzler
Independent Chairman of the Board23.3yrsUS$816.96k1.95%
$ 64.9m
David Southwell
Independent Director18.9yrsUS$438.98k0.014%
$ 453.8k
Eric Jacobsen
Member of the Scientific Advisory Boardno dataVeri yokVeri yok
Emma Reeve
Independent Director5.9yrsUS$441.98k0.0093%
$ 311.4k
Joseph Puglisi
Member of Scientific Advisory Board21yrsVeri yokVeri yok
Glenn Steele
Independent Director9.4yrsUS$426.98k0.014%
$ 453.8k
Marvin Wickens
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Robert Schneider
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Stephanie Okey
Independent Director5.9yrsUS$421.98k0.0076%
$ 253.7k

9.4yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PTCT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.4 yıldır).